Recursion and Exscientia Shareholders Approve the Proposed Combination

Contributed by: GlobeNewswire

Tags

biotech

More Like This

GlobeNewswire associated0

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

GlobeNewswire associated0

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024

Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference